Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 5/20 | 0.33 |
| ▸ | CTSL | P07711 | 4/20 | 0.33 |
| ▸ | CTSV | O60911 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 4/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870549 | 0.84 | CTSL (0.37) | CTSSCTSLCTSVSMN1; SMN2CTSK | |
| SCHEMBL5870360 | 0.83 | ALDH1A1 (0.40) | CTSSCTSLCTSVSMN1; SMN2CTSK | |
| SCHEMBL5870500 | 0.82 | CTSS (0.34) | OPRK1CTSSCTSLCTSVCTSK | |
| SCHEMBL5870275 | 0.81 | CTSC (0.43) | CTSSCTSLCTSVSMN1; SMN2CTSK | |
| SCHEMBL5870539 | 0.81 | SLC1A3 (0.34) | OPRK1CTSSCTSLCTSVCTSK | |
| SCHEMBL5870371 | 0.77 | C5AR1 (0.36) | OPRK1CTSSCTSLCTSVSMN1; SMN2 | |
| SCHEMBL6803771 | 0.74 | CTSS (0.54) | CTSSCTSLCTSVCTSK | |
| SCHEMBL6300240 | 0.74 | OPRK1 (0.32) | OPRK1 | |
| SCHEMBL4450179 | 0.73 | CTSS (0.49) | CTSSCTSLCTSVCTSK | |
| SCHEMBL14347626 | 0.73 | NAAA (0.40) | CTSSCTSLCTSVNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | OPRK1 4299/4885CTSS 24/4885CTSL 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.